Zobrazeno 1 - 10
of 74
pro vyhledávání: '"P. S. Freedman"'
Autor:
Simon Thebault, Seyed-Mohammad Fereshtehnejad, Hailey P Bergman, Gautier Breville, Mohammad Abdoli, Ronald A. Booth, Giulia Fadda, Mark S. Freedman, Gauruv Bose
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Our objective was to evaluate the individual and combined prognostic attributes of baseline serum and CSF measurements of Neurofilament light chain (sNfL, cNfL) and glial fibrillary acidic protein (sGFAP, cGFAP) on long term clinical outcome
Externí odkaz:
https://doaj.org/article/a1447839e38c4287b70e0faf39c562e8
Autor:
Sivan Ben Avraham, Angela Chetrit, Nirit Agay, Laurence S. Freedman, Walid Saliba, Uri Goldbourt, Lital Keinan-Boker, Ofra Kalter-Leibovici, Danit R. Shahar, Lizie Kimron, Rachel Dankner
Publikováno v:
Nutrition Journal, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Background Collection of detailed dietary data is labor intensive and expensive, harmonization of existing data sets has been proposed as an effective tool for research questions in which individual studies are underpowered. Methods In this
Externí odkaz:
https://doaj.org/article/9a8c3b5c65424739b99795bb5907f1b5
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 10 (2024)
Aim: Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus OZA and IFN. We compared DRF versus
Externí odkaz:
https://doaj.org/article/6731514328ba4c679fdb9725da266113
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 4, Pp 842-855 (2024)
Abstract Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety
Externí odkaz:
https://doaj.org/article/3b35a014dd2647ea854c658e2d16a68d
Autor:
Jeffrey S Miller, Martin Felices, Shee Kwan Phung, Anders W Matson, Sam Wang, Ryan R Friess, Bruce Walcheck, Kate J Dixon, Jianming Wu, Rob Hullsiek, Anders J Lindstedt, Tanya S Freedman, Emily N Truckenbrod
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Natural killer (NK) cells are being extensively studied as a cell therapy for cancer. These cells are activated by recognition of ligands and antigens on tumor cells. Cytokine therapies, such as IL-15, are also broadly used to stimulate en
Externí odkaz:
https://doaj.org/article/5e8cbf8ebe014603ad1dd5faf7ed4016
Autor:
Mark S. Freedman, Patricia K. Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich, Anthony T. Reder
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 283-322 (2024)
Abstract Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurr
Externí odkaz:
https://doaj.org/article/8f4b63ea68774d85b40c2425f80dbef2
Autor:
Damien M Rasmussen, Manny M Semonis, Joseph T Greene, Joseph M Muretta, Andrew R Thompson, Silvia Toledo Ramos, David D Thomas, William CK Pomerantz, Tanya S Freedman, Nicholas M Levinson
Publikováno v:
eLife, Vol 13 (2024)
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using
Externí odkaz:
https://doaj.org/article/908aea3f4eb7430b8ef82e94417a536d
Autor:
Jiwon Oh, Paul S. Giacomini, V. Wee Yong, Fiona Costello, François Blanchette, Mark S. Freedman
Publikováno v:
Journal of Central Nervous System Disease, Vol 16 (2024)
Significant advances have been made in the diagnosis and treatment of multiple sclerosis in recent years yet challenges remain. The current classification of MS phenotypes according to disease activity and progression, for example, does not adequatel
Externí odkaz:
https://doaj.org/article/cfcc248582ad478a95d0dd3924e71d48
Autor:
Jens Kuhle, David Leppert, Giancarlo Comi, Nicola de Stefano, Ludwig Kappos, Mark S. Freedman, Andrea Seitzinger, Sanjeev Roy
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: In REFLEX, subcutaneous interferon beta-1a (sc IFN β-1a) delayed the onset of multiple sclerosis (MS) in patients with a first clinical demyelinating event (FCDE). Objectives: This post hoc analysis aimed to determine whether baseline se
Externí odkaz:
https://doaj.org/article/d8fa4f91b5374206af1b0e490b8d88a2
Autor:
Mark S. Freedman, Sharmilee Gnanapavan, Ronald A. Booth, Peter A. Calabresi, Michael Khalil, Jens Kuhle, Jan Lycke, Tomas Olsson
Publikováno v:
EBioMedicine, Vol 101, Iss , Pp 104970- (2024)
Summary: Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There is now substantial evidence for this biomarker to be
Externí odkaz:
https://doaj.org/article/4e3c083cc88e45e594ebc2a3e2e3dc56